Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 71.8% in September

Key Points

• Short interest in Pharming Group N.V. decreased by 71.8% in September, dropping from 11,000 shares to 3,100 shares.
• Despite the reduction in short interest, analysts have differing views, with Zacks Research moving their rating from "strong-buy" to "hold".
• Pharming Group's stock has experienced a decline of 2.6% recently, currently priced at $14.00, with a market capitalization of approximately $959.21 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 3,100 shares, a decline of 71.8% from the September 15th total of 11,000 shares. Based on an average trading volume of 11,500 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 11,500 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PHAR. Zacks Research lowered Pharming Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 30th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Pharming Group in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $30.00.

Pharming Group Stock Down 2.6%

PHAR stock opened at $14.00 on Friday. Pharming Group has a twelve month low of $7.31 and a twelve month high of $17.08. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $959.21 million, a PE ratio of -107.69 and a beta of 0.04. The stock has a 50-day simple moving average of $14.06 and a two-hundred day simple moving average of $11.40.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The company had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, equities analysts predict that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.